Clinical trials: Liver Fibrosis/NASH
Obesity
Evaluation of Liver Fibrosis Following Surgical-induced Weight Loss
Obesity is a frequent disease with an increased prevalence, estimated to 12.4% in France (OBEPI study 2006). Non alcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis (NASH) both complicate morbid obesity and…
- Trial name
- FIBROTEST (NCT01469962)
- Testing
- Surgical procedure
- Where
- France
- Volunteers
- 255 people
- Sponsor
- University Hospital, Rouen
HBV, NAFLD
Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibrosis Among Patients With Hepatitis B, Hepatitis C Infection or Non Alcoholic Fatty Liver Disease
Chronic liver diseases of differing etiologies are among the leading causes of morbidity and mortality worldwide [1]. Chronic liver disease progresses through different pathological stages that vary from mild hepatic inflammation…
- Conditions
- HBV, NAFLD, HCV
- Trial name
- NCT02658786
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Chronic Kidney Diseases, NAFLD
Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with…
- Trial name
- NAFLD (NCT04779905)
- Testing
- urinary albumbin/creatinine ratio
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Sohag University
Colorectal Adenoma, Colorectal Neoplasm
ObeSity Related Colorectal Adenoma Risk
In the UK, around 1 in 16 men and 1 in 20 women will develop bowel cancer at some point in their lives. Most bowel cancers happen when a type of growth in the bowel called an adenoma eventually becomes cancerous.
- Conditions
- Colorectal Adenoma, Colorectal Neoplasm, Colorectal Cancer, Obesity
- Trial name
- OSCAR (NCT03663062)
- Testing
- Colonoscopy
- Where
- 12 sites in United Kingdom
- Volunteers
- 1,430 people
- Sponsor
- South Tyneside and Sunderland NHS Foundation Trust
Non Alcoholic Steatohepatitis
The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
To study the effects of Hesperidin and flaxseed supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to…
- Trial name
- NCT03377153
- Testing
- hesperidin and flaxseed, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Non-alcoholic Fatty Liver Disease
Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a condition where accumulation of fat in the liver leads to metabolic dysfunction. Currently there are no approved treatments for NAFLD.
- Trial name
- NCT02568605
- Testing
- Prebiotic fibre, Weight Loss
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Nonalcoholic Steatohepatitis (NASH)
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT02854605
- Testing
- GS-9674
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Non-Alcoholic Fatty Liver Disease
Serum Ferritin as a Non-invasive Marker in Prediction of Hepatic Fibrosis Among NAFLD Patients
This study was designed to assess the relation between serum ferritin and hepatic fibrosis in patients with NAFLD. It included 83 patients with NAFLD with or without hepatic fibrosis, in addition to 30 healthy subjects included…
- Trial name
- NCT03250572
- Testing
- serum ferritin
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism
Hypothyroidism and Liver Fibrosis Severity in MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, characterized by excess fat accumulation in the liver associated with metabolic risk factors such as obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07793279
- Volunteers
- 85 people
- Sponsor
- Assiut University
Non Alcoholic Steatohepatitis
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
This study aims to evaluate the possible beneficial effect of empagliflozin versus pioglitazone on non-diabetic patients with non-alcoholic steatohepatitis (NASH). This study will be a randomized, comparative parallel study.
- Trial name
- NCT05605158
- Testing
- Pioglitazone 30mg, Empagliflozin 10 MG
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Tanta University
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Cohort Study
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN-C (NCT05740358)
- Where
- 14 sites in United States
- Volunteers
- 1,222 people
- Sponsor
- Northwestern University
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris